4.5 Survivorship Care Planning & Late Effects Management

2.2 Cancer Survivorship Care Planning & Late Effects Management

Clinical Pearl: Long-term toxicity monitoring requires understanding the distinction between acute, long-term, and late adverse effects. Acute effects occur during therapy and resolve upon drug clearance; long-term effects begin during treatment and persist post-therapy (e.g., CIPN); late effects manifest months to decades after therapy completion (e.g., radiation-induced secondary malignancies or anthracycline cardiomyopathy).

Principles of Survivorship Care & Care Plan Delivery

Cancer survivorship begins at the time of diagnosis and continues throughout the balance of life. Upon completing primary curative-intent antineoplastic therapy, patients undergo a critical care transition. As established by the National Academy of Medicine (formerly IOM), American Society of Clinical Oncology (ASCO), and Commission on Cancer (CoC), every survivor must be provided a comprehensive Survivorship Care Plan (SCP).

Essential Components of a Survivorship Care Plan

1. Treatment Summary: Detailed documentation of cancer diagnosis, stage, histology, surgery performed, specific chemotherapy agents (including cumulative doses of anthracyclines and alkylating agents), radiation therapy parameters (total dose, fractions, anatomical fields), targeted agents, biologic therapies, and major acute complications.
2. Follow-Up & Surveillance Schedule: Clear timelines for oncology follow-up visits, diagnostic imaging, lab work, endoscopic surveillance, and tumor markers tailored to recurrence risk windows.
3. Late Toxicity Monitoring: Explicit guidance regarding organ-specific late toxicities based on prior exposure history.
4. Health Promotion & Risk Reduction: Guidelines for physical activity, nutrition, smoking cessation, alcohol limitation, sun protection, and immunizations.
5. Care Coordination: Explicit assignment of responsibilities between oncology specialist care and primary care providers.

---

Organ-Specific Late Toxicities & Surveillance Guidelines

---

Late Toxicities of Radiation Therapy & Systemic Therapies

Cardiovascular Toxicity

Anthracycline-induced cardiotoxicity results from topoisomerase II-beta cleavage and reactive oxygen species generation, causing irreversible cardiomyocyte loss and myocyte vacuolization. Risk correlates strictly with cumulative dose (doxorubicin threshold 450–550 mg/m²; epirubicin 900 mg/m²). Thoracic radiation accelerates coronary artery atherosclerosis, pericardial constriction, and conduction defects. Combined exposure to anthracyclines and chest radiation multiplies cardiac failure risk.

Secondary Malignancies

Secondary primary cancers account for approximately 18% of all cancer diagnoses in the United States.

• Therapy-Related Myeloid Malignancies (t-MDS/t-AML): Alkylating agents (cyclophosphamide, melphalan) induce t-MDS/t-AML with a characteristic latency of 5–7 years, frequently associated with deletions of chromosome 5 or 7. Topoisomerase II inhibitors (etoposide, doxorubicin) induce t-AML with a shorter latency (1–3 years), typically characterized by 11q23 (MLL gene) balanced translocations.
• Radiation-Induced Solid Tumors: Radiation-induced solid tumors (e.g., breast, lung, thyroid, sarcoma, non-melanoma skin cancer) occur within or adjacent to prior radiation fields, with a minimum latency period of 10 to 30 years. Women receiving mantle radiation for Hodgkin lymphoma before age 30 carry a cumulative lifetime breast cancer risk approaching 30%–40%.

Radiation Exposure (e.g., Mantle Field <30 yrs old)
  │
  ▼ Latency Period (8-10 Years)
DNA Double-Strand Damage & Genomic Instability
  │
  ▼ High Risk Window (Age 25+ or 8-10 yrs post-RT)
Initiate Dual Screening Protocol:
  ├─ Annual Contrast-Enhanced Breast MRI
  └─ Annual Digital Mammography

---

Management of Chronic Survivorship Symptoms

Cancer-Related Fatigue (CRF)

CRF is a distressing, persistent, subjective sense of physical, emotional, or cognitive tiredness related to cancer or treatment that is not proportional to recent activity and interferes with usual functioning.

• Workup: Evaluate for treatable underlying etiologies: anemia, thyroid dysfunction, sleep apnea, depression, nutritional deficiencies, and pain.
• Interventions: Structured aerobic physical activity (e.g., 150 minutes/week of moderate intensity exercise) possesses the highest level of empirical evidence (Category 1) for reducing CRF. Psychosocial interventions (Cognitive Behavioral Therapy for Fatigue [CBT-F]) are highly effective. Pharmacologic agents (e.g., methylphenidate, modafinil) show limited benefit and are reserved for select advanced cases.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN presents as a stocking-glove distribution of sensory loss, paresthesias, dysesthesias, and neuropathic pain.

• First-Line Therapy: Duloxetine (60 mg once daily) is the only pharmacologic agent recommended by ASCO guidelines with high-quality randomized evidence for painful CIPN.
• Non-Pharmacologic Support: Physical therapy, balance training, occupational safety modifications, and fall prevention protocols.

Cancer-Related Cognitive Impairment (CRCI / "Chemobrain")

Deficits in executive function, working memory, processing speed, and verbal fluency affect 20%–30% of post-chemotherapy survivors. Management emphasizes neuropsychological evaluation, cognitive rehabilitation strategies, mindfulness-based stress reduction (MBSR), and treating co-morbid sleep disturbance or distress.